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Abstract
Background: C-type natriuretic peptide (CNP) has recently been identified as an important
anabolic regulator of endochondral bone growth, but the molecular mechanisms mediating its
effects are not completely understood.
Results: We demonstrate in a tibia organ culture system that pharmacological inhibition of p38
blocks the anabolic effects of CNP. We further show that CNP stimulates endochondral bone
growth largely through expansion of the hypertrophic zone of the growth plate, while delaying
mineralization. Both effects are reversed by p38 inhibition. We also performed Affymetrix
microarray analyses on micro-dissected tibiae to identify CNP target genes. These studies
confirmed that hypertrophic chondrocytes are the main targets of CNP signaling in the growth
plate, since many more genes were regulated by CNP in this zone than in the others. While CNP
receptors are expressed at similar levels in all three zones, cGMP-dependent kinases I and II,
important transducers of CNP signaling, are expressed at much higher levels in hypertrophic cells
than in other areas of the tibia, providing a potential explanation for the spatial distribution of CNP
effects. In addition, our data show that CNP induces the expression of NPR3, a decoy receptor for
natriuretic peptides, suggesting the existence of a feedback loop to limit CNP signaling. Finally,
detailed analyses of our microarray data showed that CNP regulates numerous genes involved in
BMP signaling and cell adhesion.
Conclusion: Our data identify novel target genes of CNP and demonstrate that the p38 pathway
is a novel, essential mediator of CNP effects on endochondral bone growth, with potential
implications for understanding and treatment of numerous skeletal diseases.
Background
Bone formation occurs through the related, but distinct
processes of intramembranous and endochondral ossifi-
cation [1,2]. While the former is responsible for the for-
mation of bones directly from precursor cells, such as the
majority of the skull, the latter is responsible for the devel-
opment of long bones, ribs, and vertebrae through a carti-
lage intermediate. In endochondral ossification,
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mesenchymal cells condense and begin to differentiate
into chondrocytes, some of which later form the growth
plate that controls longitudinal growth of endochondral
bones [3]. The growth plate zones consists of resting, pro-
liferating, and terminally differentiated hypertrophic
chondrocytes, each of which are characterized by the
expression of specific markers [4,5]. This organization of
the growth plate and the coordinated proliferation and
hypertrophy of chondrocytes are responsible for elonga-
tion of bones and eventually determine final bone length.
Hypertrophic chondrocytes are thought to undergo apop-
tosis, and simultaneously their surrounding cartilaginous
matrix is degraded and replaced by bony tissue, produced
by cells entering through vascularization of hypertrophic
cartilage. The intricate control mechanisms regulating the
proliferation, differentiation and apoptosis of chondro-
cytes as well as the subsequent vascular invasion are not
completely understood. However, disturbances of these
processes can result in numerous diseases such as chon-
drodysplasias and other growth disorders, demonstrating
the need for a better understanding of the pathways
involved [4,6-9].
C-type natriuretic peptide (CNP) has recently been shown
to be an important regulator of endochondral ossifica-
tion. The dominant phenotype of CNP-deficient mice is
dwarfism, as demonstrated by shortened long bones pri-
marily due to reduced heights of proliferating and hyper-
trophic zones of the growth plate [10,11]. CNP also
increases growth in mouse bone organ cultures [12,13].
More recently, loss-of-function mutations in NPR2, the
gene encoding the CNP receptor, have been identified as
cause of acromesomelic dysplasia type Maroteaux, an
autosomal recessive chondrodysplasia in humans [14].
This CNP receptor is also known as guanylyl cyclase-B
(GC-B) or NPR-B. Binding of CNP to GC-B results in
increased intracellular cGMP, which can further activate
downstream factors, such as cGKI and cGKII (cGMP-
dependent protein kinase I and II) as well as phosphodi-
esterases (PDEs) that break down cGMP and camp and
specific ion channels [15-18]. In addition, CNP can also
bind to a different receptor, NPR-3 (natriuretic peptide
receptor 3) that is thought to act as a decoy/clearance
receptor serving to limit the effects of natriuretic peptides.
Interestingly, mice deficient for cGKII show a similar,
although not identical phenotype to CNP-deficient mice
[19], and cGKII has been shown to be required for the
effects of CNP overexpression in transgenic mice [20].
These data clearly identify cGKII as an essential mediator
of CNP effects, but the signaling pathways downstream of
cGKII, potential parallel pathways and the target genes
conferring cartilage responses to CNP are not completely
understood. However, recent studies showed that overex-
pression of CNP results in inhibition of the MEK1/2-
ERK1/2 MAP kinase pathway and rescues the effects of an
activating fibroblast growth factor receptor 3 mutation on
endochondral bone growth [21-23].
MAP kinases are central signaling molecules in most
eukaryotic cells that integrate extracellular signals leading
to altered cell proliferation, differentiation, and transcrip-
tion in many cell types, including chondrocytes [24,25].
For example, both the ERK and the p38 MAPK families
have been shown to play important roles in controlling
chondrocyte differentiation in vitro and in vivo [3,26,27].
In the current study we demonstrate, for the first time, an
essential role for the p38 MAP kinase pathway in CNP sig-
naling in cartilage and identify target genes of CNP in
chondrocytes using genome-wide microarrays.
Results
CNP signaling enhances endochondral bone growth
We used an organ culture system of embryonic day 15.5
(E15.5) mouse tibiae to examine the effects of CNP on
endochondral bone growth. Tibiae were cultured for six
days in the presence of BSA (control) or different concen-
trations of CNP. 10-8, 10-7 and 10-6M concentrations of
CNP caused a 31%, 40%, and 42% increase, respectively,
in longitudinal growth of tibiae (Fig. 1A,B). Treatment
with 1 μM CNP almost doubled tibia weight relative to
controls (Fig. 1C). Incubation of tibiae with 10-4 M (8-(4-
chlorophenylthio) cGMP stimulated tibia growth in a
similar or stronger manner (55%) as CNP (Fig. 1D). A
general inhibitor of phosphodiesterases (PDEs), 3-Iso-
butyl-1-methylxanthine (IBMX) at 10-4 M, was used to
study the role of PDEs in bone growth in the organ cul-
tures. PDE inhibition stimulated longitudinal growth by
30% when compared to the control. In contrast, specific
inhibition of PDE 1 by 8-methoxymethyl IBMX did not
alter bone growth significantly, indicating that this
enzyme is either not involved in regulating bone growth
or can be functionally replaced by other proteins. These
data demonstrate that CNP/cGMP signaling stimulates
endochondral bone growth, while PDEs inhibit this proc-
ess. Removal of the perichondrium by enzymatic diges-
tion and/or manual dissection did not alter the response
to CNP, demonstrating that the anabolic effects of CNP
are independent of the perichondrium (Fig. 1E).
At the histological level, the most significant effect of CNP
was a marked expansion of the hypertrophic zone (Fig.
2A). This enlargement of the hypertrophic zone was
accomplished by increases in both the number and maxi-
mal size of hypertrophic chondrocytes (Fig. 2B), in agree-
ment with earlier studies [23].
CNP-induced endochondral bone growth requires p38 
MAP kinase signaling
MAP kinases play multiple roles in chondrocyte differen-
tiation and cartilage development [3]. We therefore exam-BMC Developmental Biology 2007, 7:18 http://www.biomedcentral.com/1471-213X/7/18
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CNP enhances endochondral bone growth Figure 1
CNP enhances endochondral bone growth. Mouse E15.5 tibiae were harvested and cultured for six days in the presence 
of vehicle, CNP at the indicated concentrations, membrane-permeable 8-(4-cpt) cGMP (0.1 mM), the non-specific PDE inhibi-
tor IBMX (0.1 mM), or a selective inhibitor of PDE I, 8-methooxymethyl, IBMX (10 μM). After six days in culture, vehicle and 
CNP-treated (1 μM) bones were stained with Alcian Blue and Alizarin Red and representative images are shown, in compari-
son to a freshly isolated tibia (A). Growth of tibiae over the culture period at indicated concentrations of CNP and treatments 
was measured (B, D), and the weight of bones was determined (C). CNP, 8-(4-cpt) cGMP and IBMX stimulated tibia growth, 
when compared to control conditions. E15.5 tibiae were isolated under three different conditions: perichondrium was left 
intact with very loose dissection, perichondrium was removed with dispase, and perichondrium was removed mechanically (E). 
Bones were then incubated with or without CNP (1 μM) for six days and bone growth was determined as change in bone 
length relative to day 1. Removal of the perichondrium did not influence the stimulatory effect of CNP on bone growth. All 
data represent means ± SD of three or four independent trials (p < 0.05).
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ined a potential role of the MEK (MAP/ERK kinase) 1/2-
ERK1/2 and p38 cascades in CNP-induced endochondral
bone growth. In the absence of exogenous CNP, the phar-
macological MEK1/2 inhibitors PD98059 and U0126 (10
μM each) stimulated tibia growth by 39% and 30%,
respectively (Fig. 3A). While simultaneous addition of
MEK inhibitors and CNP had maximal effects on bone
growth, these effects were not statistically different from
treatment with CNP alone. These data suggest that CNP
and MEK1/2 act through a common pathway and are in
agreement with recent studies demonstrating an inhibi-
tory role of the MEK/ERK cascade in endochondral bone
growth [26] and down-regulation of MEK/ERK activity by
CNP [21-23].
We next examined whether p38 is involved in the effects
of CNP on cartilage growth. Inhibition of p38 activity by
two different compounds, PD169316 or SB202190 (10
μM each), did not affect basal endochondral bone growth,
when compared to the inactive control compound
SB202474 (10 μM) (Fig. 3B). In contrast, inhibition of
p38 by SB202190 or PD169316 blocked CNP-induced
growth (Fig. 3B). This effect was obvious by day 6 of cul-
ture and maintained by day 8 (Fig. 3C). Moreover, p38
inhibition completely reversed CNP effects on tibia
weight (Fig. 3D), further demonstrating a requirement for
p38 activity in CNP-induced endochondral bone growth.
Next we examined whether CNP regulates the p38 path-
way by investigating the phosphorylation of the kinases
MKK3 (MAP kinase kinase3) and MKK6, direct and spe-
cific activators of p38. Western blotting with phospho-
specific antibodies revealed that CNP and cGMP increase
the phosphorylation of MKK3/6 in primary chondrocytes
after 10 minutes of incubation (Fig. 3E), demonstrating
that CNP signaling activates the p38 pathway in chondro-
cytes. Immunohistochemistry for phosphorylated (active)
p38 showed little staining under control conditions, but
demosntrated a strong increase in p38 phosphorylation in
CNP-treated tibiae (Fig. 3F).
CNP delays tibia mineralization in a p38-dependent 
manner
To examine the effects of p38 inhibition on growth plate
organization, we performed histological analyses of organ
culture sections. As above, CNP stimulation caused an
expansion of the hypertrophic zone of the growth plate,
while SB202190 by itself did not have any marked effects
(Fig. 4A). However, p38 inhibition suppressed the
enlargement of the hypertrophic zone in response to
CNP, providing further evidence for a requirement for
p38 activity for the anabolic effects of CNP.
During dissections and analyses of organ cultures, we also
noticed that CNP-treated bones were more fragile and
appeared less mineralized. Alcian Blue/Alizarin Red stain-
ing of tibiae confirmed that the mineralized area was
smaller in CNP-treated bones and displayed weaker Ali-
zarin Red staining (Fig. 4B). We quantified the area of the
mineralized (red) and cartilaginous (blue) regions of tib-
iae using digital image analyses. CNP treatment did
increase the Alcian Blue-stained area considerably, with-
out effects on the Alizarin Red-stained area (Fig. 4C). This
resulted in a reduction of the mineralized area relative to
the total area of the bone by about 30%. These data sug-
gests that CNP-induced growth of cartilage is not matched
by a corresponding expansion of the mineralized area and
that CNP treatment delays the remodeling of hyper-
trophic cartilage. Inhibition of p38 activity by SB202190
resulted in a slight, but significant increase of the mineral-
ized area (relative to total area) and reversed the effects of
CNP on the Alcian Blue-stained area completely (Fig. 4C).
Microarray analyses identify hypertrophic chondrocytes as 
main targets of CNP signaling
We next performed microarray analyses to identify target
genes of CNP in chondrocytes. Tibiae were cultured for six
days in the absence or presence of CNP and then micro-
CNP induces expansion of the hypertrophic zone Figure 2
CNP induces expansion of the hypertrophic zone. 
Hematoxylin and Eosin staining of tibia sections after six days 
of culture with or without CNP (1 μM) showed differences 
in growth plate architecture, primarily in the hypertrophic 
zone. CNP treatment results in a vastly expanded hyper-
trophic zone (A; hypertrophic zones indicated by brackets). 
Magnification of cells in the hypertrophic zone (boxes from 
A) shows that individual chondrocytes are larger in CNP-
treated tibiae (B).
A
0.25 mm
Control CNP
B
Control CNP
50 μmBMC Developmental Biology 2007, 7:18 http://www.biomedcentral.com/1471-213X/7/18
Page 5 of 23
(page number not for citation purposes)
dissected into three distinct zones: the resting/prolifera-
tive (RP), the hypertrophic (H), and the mineralized (M)
zones (Fig. 5A). RNA was isolated directly from tibiae
from three independent trials for each zone and both
treatments were analyzed using Affymetrix Mouse 2.0
arrays in the London Regional Genomics Center as
described (London, Ontario, Canada) [28]. Real-time
PCR analyses of collagen II (Col2a1) and collagen X
(Col10a1), known markers of cartilage development, con-
firmed that micro-dissection resulted in efficient separa-
tion of the zones (Fig. 5B). Microarray profiles of selected
genes involved in endochondral bone growth are shown
to further illustrate correct separation of zones (Fig. 5C).
Bioinformatics analyses of microarray results (Fig. 6A)
demonstrated that the hypertrophic zone was most
responsive to CNP (Fig. 6B). Only 47 probe sets in the
resting/proliferative zone (35 down, 12 up) and 58 probe
sets in the mineralized zone (41 down, 17 up) responded
with minimum two-fold responses to CNP (see Table 1
and 2 for lists of regulated genes). In contrast, 309 probe
sets in the hypertrophic area showed a two-fold or higher
change in expression in response to CNP. Of these probe
sets, 157 probe sets were up-regulated by CNP in the
hypertrophic zone, and 152 were down-regulated by CNP
(Table 3).
One of the genes showing a strong increase in the hyper-
trophic zone (>6-fold) was Ptgs2, encoding cyclooxygen-
ase 2 (Cox2), a key enzyme in the synthesis of
prostaglandins. Since Ptgs2 and its products (such as pros-
taglandin E2) are known to play important roles in
chondrocyte differentiation and skeletal remodeling [29-
31], we selected this gene for validation experiments.
Induction of Cox2 mRNA expression in the hypertrophic
zone by CNP was confirmed by real-time PCR, which
showed a 10-fold increase in transcript levels (Fig. 6C).
p38 inhibition did reduce the basal levels of Cox2 mRNA,
but surprisingly did not affect the induction by CNP.
Among the genes down-regulated by CNP was the Tnfsf11
gene, encoding RANKL, a known activator of osteoclastic
resorption of bone and cartilage [32,33]. Tnfsf11 dis-
played a 3.8-fold reduction in expression according to
microarray analyses. Because down-regulation of Tnfsf11
could provide a molecular mechanism for the observed
delay in mineralization and cartilage remodeling in
response to CNP, we chose to validate its expression. Real-
time PCR analysis confirmed down-regulation of Tnfsf11
mRNA levels in the hypertrophic zone by CNP (Fig 6D).
To answer the question why the hypertrophic zone is
much more responsive to CNP treatment than other
zones, we examined expression of key genes in the CNP
signaling pathway. Analyses of our microarray data dem-
onstrated that the genes encoding CNP (Nppc), its signal-
ing receptor GC-B (Npr2) and the decoy receptor (Npr3)
are expressed at similar levels in all three zones of micro-
dissected tibiae under control conditions (Fig. 7A). How-
ever, Prkg1 (encoding cGMP-dependent kinase I) expres-
sion is 5.9 fold higher in hypertrophic chondrocytes than
in the resting/proliferative cells, and seven-fold higher in
the hypertrophic versus the mineralized zone (Fig. 7A).
Similarly, Prkg2 expression is 4.4-fold and 2.5-fold higher
in the hypertrophic zone versus the resting/proliferative
and mineralized zones, respectively (Fig. 7A). This expres-
sion pattern of key mediators of CNP signaling can
explain the strong responsiveness of hypertrophic
chondrocytes to CNP. In addition, our microarray data on
expression of the decoy receptor Npr3 in the hypertrophic
zone, while variable and thus not statistically significant,
suggested that CNP strongly activates the expression of
Npr3. We therefore decided to analyze its expression by
real-time PCR which demonstrated a statistically signifi-
cant 16-fold induction of Npr3 expression in the hyper-
trophic zone by CNP that was not altered by p38
inhibition (Fig. 7B). CNP did not affect Npr3 expression
in the other growth plate zones.
Annotation of microarray data identifies CNP-regulated 
pathways
To gain insight into biological processes regulated by
CNP, we employed KEGG annotation [34] on genes
showing at least two-fold changes in response to CNP in
the hypertrophic area (Fig. 8A). Numerous pathways were
affected by CNP, most of them comprised approximately
proportionally by up- and down-regulated genes. How-
ever, genes related to cell adhesion were strongly enriched
in up-regulated genes, suggesting that CNP promotes cell
adhesion. Most notably, CNP induced expression of genes
involved in cell-cell interactions such as Icam2 (intercellu-
lar adhesion molecule 2), Cdh5 (Cadherin 5), and Esam1
(endothelial cell-specific adhesion molecule). In contrast,
down-regulated genes included many genes encoding
extracellular matrix molecules, for example Matn1  and
Matn3 (Matrilin 1 and 3), Col9a2 (procollagen type IX,
alpha 2) and Col14a1  (procollagen type XIV, alpha 1)
(Table 3). In addition, up-regulated genes included three
members of the TGFβ superfamily, Gdf5, Inhbb and Inhba,
as well as the BMP antagonist Grem1 (Fig. 8B). Besides the
TGFβ family, members of the Wnt and hedgehog signal-
ing pathways are important regulators of cartilage differ-
entiation, and components of these pathways were
regulated by CNP. Other categories in which up-regulated
genes were over-represented included tight junctions and
calcium signaling, whereas pantothenate and CoA biosyn-
thesis was one example for a pathway dominated by
down-regulated genes. Finally, more transcription factor-
encoding genes were up-regulated than down-regulated
by CNP (Fig. 8B).BMC Developmental Biology 2007, 7:18 http://www.biomedcentral.com/1471-213X/7/18
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Inhibition of the MEK1/2-ERK1/2 pathway stimulates tibia growth, while p38 MAPK is required for CNP-induced bone growth Figure 3
Inhibition of the MEK1/2-ERK1/2 pathway stimulates tibia growth, while p38 MAPK is required for CNP-
induced bone growth. Mouse E15.5 tibiae were harvested and cultured for six days in the presence of control or CNP (1 
μM) and vehicle (DMSO) or MEK1/2-ERK1/2 pathway inhibitors PD98059 (10 μM) and U0126 (10 μM) (A). Though both 
PD98059 and U0126 stimulated basal bone growth, inhibition of the MEK1/2-ERK1/2 pathway did not further enhance CNP-
induced bone growth (*: p < 0.05 when comparing control/inhibitors to control/vehicle; #: p < 0.05 when comparing CNP/
vehicle to control/vehicle; p > 0.05 when comparing CNP/vehicle to CNP/inhibitors). Tibiae were incubated with control or 
CNP and pharmacological inhibitors of the p38 MAPK pathway (SB202190 or PD169316, 10 μM each) or an inactive analog 
(SB202474, 10 μM) (B). p38 inhibition did not effect basal bone growth significantly, but did suppress CNP-induced bone 
growth (*: p < 0.05 when comparing CNP/inhibitors to CNP/SB202474; #: p < 0.05 when comparing CNP/SB202474 to con-
trol/SB202474). Bone growth was measured over an extended time course of eight days, showing that CNP continued to sig-
nificantly influence growth on day 8, while SB202190 reversed these effects (C). Bones from each treatment were weighed 
under different conditions, and it was found that p38 inhibition reversed the effects of CNP on weight (D). Protein extracts 
from primary chondrocytes cultured with control, CNP (10-6M), or 8-(4-cpt) cGMP (0.1 mM) for 10 minutes were examined 
for phosphorylation of the p38 activators MKK3/6 by western blot analysis (E). Both treatments increased phosphorylation of 
MKK3/6, supporting the stimulation of p38 MAP kinase activity by CNP signaling. Immunohistochemistry with an antibody 
against phosphorylated p38 demonstrates markedly higher signal in CNP-treated tibiae when compared to control bones (F).
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p38 MAPK activity is required for CNP-induced hypertrophy Figure 4
p38 MAPK activity is required for CNP-induced hypertrophy. E15.5 tibiae were isolated and incubated with or with-
out CNP (1 μM) and DMSO or SB202190 (10 μM). Hematoxylin and Eosin staining of tibia sections after six days of culture 
show that p38 inhibition reversed CNP-induced expansion of the hypertrophic zone (A). Tibiae were stained with Alizarin Red 
and Alcian Blue, and representative images demonstrate increased bone growth by CNP and the reversal of these effects upon 
p38 inhibition (B). The area of the mineralized zone (red) was measured as absolute area (C, bottom) and as a percentage of 
total area (C, top), demonstrating that CNP-treated bones displayed significantly smaller mineralized area in relation to the 
whole bone area. This was reversed upon p38 inhibition. Representative images are shown, while all data represent means ± 
SD of four independent trials, each with six bones (p < 0.05).
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Micro-dissection efficiently separates different growth plate zones from cultured tibiae Figure 5
Micro-dissection efficiently separates different growth plate zones from cultured tibiae. E15.5 tibiae that were 
harvested and incubated with or without CNP (1 μM) for six days were micro-dissected into the resting/proliferating, hyper-
trophic, and mineralized regions as shown (A). Zones from approximately 24 bones were pooled together. RNA was isolated 
directly from micro-dissected tibia and analyzed by microarray as described in Materials and Methods. Real-time PCR analyses 
confirmed expected expression patterns of the cartilage markers Col2a1 and Col10a1 in control bones (B; data represent 
means ± SD from three independent trials). Expression patterns of selected chondrocyte marker genes under control condi-
tions in our microarray data sets further demonstrated efficient separation of regions (C).
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Microarray analyses identify the hypertrophic area as the main target of CNP treatment Figure 6
Microarray analyses identify the hypertrophic area as the main target of CNP treatment. E15.5 tibiae were iso-
lated, incubated with or without CNP (1 μM) and DMSO or SB202190 (10 μM) and micro-dissected into the resting/proliferat-
ing, hypertrophic, and mineralized regions prior to RNA extraction and microarray analyses. Analyses of microarray results 
from three independent trials using Genespring 7.2 (A) illustrated that the hypertrophic zone was most significantly responsive 
to CNP treatment, when compared to control conditions (B). Six times as many probe sets showed at least 2-fold expression 
changes in the hypertrophic zone when compared to either resting/proliferating or mineralized regions. Real-time PCR analy-
ses on micro-dissected tibiae were used to validate selected microarray patterns. CNP induction of Ptgs2, the gene encoding 
cyclooxygenase-2, was confirmed (C). SB202190 treatment did reduce basal Cox2 mRNA levels, but did not interfere with 
CNP induction of Cox2. Tnfsf11, the gene encoding RANKL, was confirmed to be down-regulated in response to CNP treat-
ment. Data represent means ± SD of three independent trials (p < 0.05).
A
B
CD
N
u
m
b
e
r
 
o
f
 
P
r
o
b
e
 
S
e
t
s
   Resting/
Proliferating  Hypertrophic Mineralized
47 58
309
0
50
100
150
200
250
300
350
Control CNP SB202190     CNP+
SB202190
Relativ
e 
Ptgs2
Expr
ession/
Gapdh
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35 *
*
Control CNP Control CNP Control CNP
0.01
0.1
1
10
Resting/Proliferating Hypertrophic Mineralized
N
o
r
m
a
l
i
z
e
d
 
I
n
t
e
n
s
i
t
y
 
(
l
o
g
 
s
c
a
l
e
)
100
R
e
l
a
t
i
v
e
 
T
n
f
s
f
1
1
 
E
x
p
r
e
s
s
i
o
n
/
G
a
p
d
h
Control CNP
0
0.2
0.4
0.6
0.8
1
1.2
*BMC Developmental Biology 2007, 7:18 http://www.biomedcentral.com/1471-213X/7/18
Page 10 of 23
(page number not for citation purposes)
We also performed KEGG analyses of CNP-regulated
genes in the other zones. In the proliferative zone, genes
involved in cytokine receptor interactions were most
prominent with four genes, three of each were upregu-
lated by CNP (Table 1). The categories of cell adhesion
and focal adhesion molecules were represented by three
genes each (data not shown). In contrast, no category was
represented by more than two genes in the mineralized
zone (data not shown).
Discussion
Gene disruption and other studies have identified the
CNP pathway as one of the most important anabolic reg-
ulators of endochondral bone growth. However, the
molecular and cellular mechanisms involved are not com-
pletely understood. Here we provide multiple novel
insights into these mechanisms. Most importantly, we
show that the p38 MAP kinase pathway is an essential
mediator of CNP effects on endochondral bone growth.
Second, we identify the hypertrophic zone of the growth
plate as the main target of CNP signaling, likely because
of the high levels of cGMP-dependent kinase I and II
expression in this zone. Third, we used genome-wide
microarray analyses to identify multiple target genes
potentially involved in CNP effects in cartilage.
Earlier studies have demonstrated that CNP stimulates
bone growth through enhanced proliferation, mineraliza-
Table 1: Genes showing 2-fold or greater changes in resting/proliferating zone
Gene Name Gene Description Fold Change (CNP/Control)
Spock3 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 3 2.76
Il15 interleukin 15 2.73
Mgst2 microsomal glutathione S-transferase 2 2.60
Alcam activated leukocyte cell adhesion molecule 2.52
Tec cytoplasmic tyrosine kinase, Dscr28C related (Drosophila) 2.27
Aard alanine and arginine rich domain containing protein 2.24
Tnfsf11 tumor necrosis factor (ligand) superfamily, member 11 2.18
Vegfc vascular endothelial growth factor C 2.18
Senp8 SUMO/sentrin specific protease family member 8 2.09
Pde4b phosphodiesterase 4B, cAMP specific 2.02
Gcnt2 glucosaminyl (N-acetyl) transferase 2, I-branching enzyme 0.18
Cidea cell death-inducing DNA fragmentation factor, alpha subunit-like 0.24
Frzb frizzled-related protein 0.28
F5 coagulation factor V 0.31
Car8 carbonic anhydrase 8 0.32
Ibsp integrin binding sialoprotein 0.34
Lifr leukemia inhibitory factor receptor 0.36
Col10a1 procollagen, type X, alpha 1 0.37
Lepr leptin receptor 0.37
Ibsp integrin binding sialoprotein 0.38
Pthr1 parathyroid hormone receptor 1 0.38
Clcn7 chloride channel 7 0.41
Chd7 chromodomain helicase DNA binding protein 7 0.42
H2-DMa histocompatibility 2, class II, locus DMa 0.42
Col13a1 procollagen, type XIII, alpha 1 0.42
Cntn1 contactin 1 0.43
Slc7a3 solute carrier family 7, member 3 0.44
Tm7sf1 transmembrane 7 superfamily member 1 0.45
Iqsec1 IQ motif and Sec7 domain 1 0.45
Pthlh parathyroid hormone-like peptide 0.46
Pdzk3 PDZ domain containing 2 0.46
Tmie transmembrane inner ear 0.47
Ifitm5 interferon induced transmembrane protein 5 0.47
Socs2 suppressor of cytokine signaling 2 0.47
Angptl2 angiopoietin-like 2 0.48
Capn6 calpain 6 0.48
Atp10d ATPase, Class V, type 10D 0.48
Cald1 caldesmon 1 0.49
Phtf2 putative homeodomain transcription factor 2 0.50BMC Developmental Biology 2007, 7:18 http://www.biomedcentral.com/1471-213X/7/18
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tion and extracellular matrix synthesis [10,12,13]. Our
data suggest that effects of CNP on longitudinal bone
growth are largely due to the expansion of the hyper-
trophic zone, in agreement with earlier studies [23]. This
could be due, in principle, to a number of effects, such as
increased rate of generation of hypertrophic chondro-
cytes, increased size of individual hypertrophic chondro-
cytes, and delayed replacement of hypertrophic cartilage
by bone. It should be noted that these possibilities are not
exclusive, and several or all of them can contribute to the
observed effects of CNP. Multiple observations support
the notion that delayed removal of hypertrophic chondro-
cytes is one of the mechanisms involved in CNP-induced
bone growth. First, terminal hypertrophic chondrocytes at
the metaphysis reach a larger size, suggesting that a delay
in chondrocyte replacement by bone tissue allows for a
longer period of cellular growth. Furthermore, while CNP
increases the size of the entire tibia significantly, this
increase is not matched by a proportional increase in the
area of the mineralized region. This observation suggests
that CNP delays remodeling of the metaphysis and the
replacement of cartilage by bone. Finally, our microarray
Table 2: Genes showing 2-fold or greater changes in mineralized zone
Gene Name Gene Description Fold Change (CNP/Control)
Ptgs2 prostaglandin-endoperoxide synthase 2 2.87
Bcan brevican 2.75
Gabrb3 gamma-aminobutyric acid (GABA-A) receptor, 
subunit beta 3
2.46
Robo4 roundabout homolog 4 (Drosophila) 2.31
Cd38 CD38 antigen 2.23
Lepr leptin receptor 2.22
Cd24a CD24a antigen 2.15
Tgfbi transforming growth factor, beta induced 2.14
Tmem56 transmembrane protein 56 2.12
Gsg2 germ cell-specific gene 2 2.11
Dspg3 dermatan sulphate proteoglycan 3 2.11
Siat4c sialyltransferase 4C (beta-galactoside alpha-2,3-
sialytransferase)
2.04
Hbb-y hemoglobin Y, beta-like embryonic chain 0.21
Zbtb8 zinc finger and BTB domain containing 8 0.24
Chic1 cysteine-rich hydrophobic domain 1 0.27
Mia EGL nine homolog 2 (C. elegans) 0.28
Nox4 NADPH oxidase 4 0.29
Fgd6 FYVE, RhoGEF and PH domain containing 6 0.32
Ddc dopa decarboxylase 0.34
Crxos1 Crx opposite strand transcript 1 0.37
Hapln1 cartilage link protein 1 0.37
Col27a1 procollagen, type XXVII, alpha 1 0.38
Fgd5 FYVE, RhoGEF and PH domain containing 5 0.38
Msi2h Musashi homolog 2 (Drosophila) 0.39
Rgs11 regulator of G-protein signaling 11 0.42
Mrpl35 mitochondrial ribosomal protein L35 0.43
Wwp2 WW domain containing E3 ubiquitin protein 
ligase 2
0.44
Glt25d2 glycosyltransferase 25 domain containing 2 0.44
Zcchc5 zinc finger, CCHC domain containing 5 0.45
Stno strawberry notch homolog (Drosophila) 0.46
Ppp1r3c protein phosphatase 1, regulatory (inhibitor) 
subunit 3C
0.46
Col9a3 procollagen, type IX, alpha 3 0.47
Igf2 insulin-like growth factor 2 0.47
Edil3 EGF-like repeats and discordin I-like domains 3 0.48
Ttll3 tubulin tyrosine ligase-like family, member 3 0.48
A2m alpha-2-macroglobulin 0.49
Ctf1 cardiotrophin 1 0.49
Xist inactive X specific transcripts 0.49
Zfp458 zinc finger protein 458 0.50BMC Developmental Biology 2007, 7:18 http://www.biomedcentral.com/1471-213X/7/18
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Table 3: Genes showing 2-fold or greater changes in hypertrophic zone
Gene Name Gene Description Fold Change (CNP/Control)
Cxcl14 chemokine (C-X-C motif) ligand 14 7.15
Ptgs2 prostaglandin-endoperoxide synthase 2 6.77
Grem1 cysteine knot superfamily 1, BMP antagonist 1 6.47
Fbxo32 F-box only protein 32 5.87
Glipr1 GLI pathogenesis-related 1 (glioma) 5.22
Gdf5 growth differentiation factor 5 4.93
Nox4 NADPH oxidase 4 3.78
Ebi2 Epstein-Barr virus induced gene 2 3.78
Evi1 ecotropic viral integration site 1 3.50
Prnd prion protein dublet 3.43
Acdc adipocyte complement related protein 3.42
Nes nestin 3.33
Tnnt3 troponin T3, skeletal, fast 3.29
Nox4 NADPH oxidase 4 3.27
Rbp1 retinol binding protein 1, cellular 3.19
Hist1h2bc histone 1, H2bp 3.16
Inhbb inhibin beta-B 3.12
Sox17 SRY-box containing gene 17 3.10
Rnf125 ring finger protein 125 3.08
Fabp4 fatty acid binding protein 4, adipocyte 3.07
C1ql3 C1q-like 3 3.03
Rbpms RNA binding protein gene with multiple splicing 3.02
Nrarp Notch-regulated ankyrin repeat protein 3.02
Mmrn2 multimerin 2 3.00
Cldn5 claudin 5 3.00
Cd44 CD44 antigen 2.99
Klhl4 kelch-like 4 (Drosophila) 2.98
Pscd4 pleckstrin homology, Sec7 and coiled/coil 
domains 4
2.90
Ptprc protein tyrosine phosphatase, receptor type, C 2.86
Rasgrp1 RAS guanyl releasing protein 1 2.85
Ptger2 prostaglandin E receptor 2 (subtype EP2) 2.84
Ctla2b trophoblast specific protein beta 2.84
Copg2as2 coatomer protein complex, subunit gamma 2, 
antisense 2
2.82
Ian1 immune associated nucleotide 1 2.82
Pmaip1 phorbol-12-myristate-13-acetate-induced 
protein 1
2.77
Gpihbp1 GPI-anchored HDL-binding protein 1 2.73
Cdh5 cadherin 5 2.69
Niban niban protein 2.67
Ptpn3 protein tyrosine phosphatase, non-receptor 
type 3
2.67
Slc26a7 solute carrier family 26, member 7 2.67
Tm6sf1 transmembrane 6 superfamily member 1 2.65
Pkp2 plakophilin 2 2.65
Bcl2a1a B-cell leukemia/lymphoma 2 related protein 
A1a
2.63
Prss8 protease, serine, 8 (prostasin) 2.61
Fads3 fatty acid desaturase 3 2.60
Runx1 runt related transcription factor 1 2.56
Abcc9 ATP-binding cassette, sub-family C (CFTR/
MRP), member 9
2.56
Nr2f1 nuclear receptor subfamily 2, group F, member 
1
2.55
Hbb-y hemoglobin Y, beta-like embryonic chain 2.52
Akr1b8 aldo-keto reductase family 1, member B8 2.51
Siat8f sialyltransferase 8 (alpha-2, 8-sialyltransferase) 
F
2.51
Sfpi1 SFFV proviral integration 1 2.51BMC Developmental Biology 2007, 7:18 http://www.biomedcentral.com/1471-213X/7/18
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Zbtb33 zinc finger and BTB domain containing 33 2.49
Gdpd1 glycerophosphodiester phosphodiesterase 
domain containing 1
2.46
Clecsf6 C-type lectin, superfamily member 6 2.46
Pstpip1 proline-serine-threonine phosphatase-
interacting protein 1
2.45
Esam1 endothelial cell-specific adhesion molecule 2.44
Cdh13 cadherin 13 2.43
Hist2h3c2 histone 2, H2aa1 2.43
Sfrp2 secreted frizzled-related sequence protein 2 2.40
Cables1 Cdk5 and Abl enzyme substrate 1 2.39
Ednrb endothelin receptor type B 2.39
Eltd1 EGF, latrophilin seven transmembrane domain 
containing 1
2.38
Calcrl calcitonin receptor-like 2.38
Ctla2b trophoblast specific protein beta 2.38
Ian1 immune associated nucleotide 1 2.36
Sox18 SRY-box containing gene 18 2.36
Plce1 phospholipase C, epsilon 1 2.33
Il13ra1 interleukin 13 receptor, alpha 1 2.33
Cd38 CD38 antigen 2.32
Ncf4 neutrophil cytosolic factor 4 2.30
Rgs4 regulator of G-protein signaling 4 2.30
Ptpn8 protein tyrosine phosphatase, non-receptor 
type 8
2.29
Inhba inhibin beta-A 2.29
Alcam activated leukocyte cell adhesion molecule 2.27
Pira1 paired-Ig-like receptor A1 2.27
Cav2 caveolin 2 2.27
Cxcr4 chemokine (C-X-C motif) receptor 4 2.26
Sh3bp5 calpain 7 2.26
Mfap3l microfibrillar-associated protein 3-like 2.26
Dscr1 Down syndrome critical region homolog 1 
(human)
2.25
Mcam melanoma cell adhesion molecule 2.24
Ms4a6d membrane-spanning 4-domains, subfamily A, 
member 6D
2.24
Cd34 CD34 antigen 2.24
Zfp42 zinc finger protein 42 2.23
Kcne3 potassium voltage-gated channel, Isk-related 
subfamily, gene 3
2.22
Ivns1abp influenza virus NS1A binding protein 2.22
Cd84 CD84 antigen 2.22
Kdr kinase insert domain protein receptor 2.21
Clca5 chloride channel calcium activated 5 2.20
Itga9 integrin alpha 9 2.19
Prkch protein kinase C, eta 2.19
Tex15 testis expressed gene 15 2.18
Plac8 placenta-specific 8 2.17
Ebf3 early B-cell factor 3 2.16
Lcp2 lymphocyte cytosolic protein 2 2.16
Mcoln3 mucolipin 3 2.15
Sh3glb1 SH3-domain GRB2-like B1 (endophilin) 2.15
Ugt1a2 UDP glycosyltransferase 1 family, polypeptide 
A6
2.15
Egfl7 EGF-like domain 7 2.15
Icam2 intercellular adhesion molecule 2 2.15
Six1 sine oculis-related homeobox 1 homolog 
(Drosophila)
2.14
Chst7 carbohydrate (N-acetylglucosamino) 
sulfotransferase 7
2.13
Evi2a ecotropic viral integration site 2a 2.12
Myct1 myc target 1 2.12
Pde4b phosphodiesterase 4B, cAMP specific 2.12
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Adamts1 a disintegrin-like & metalloprotease with 
thrombospondin type 1
2.10
Snx10 sorting nexin 10 2.10
Rac2 RAS-related C3 botulinum substrate 2 2.09
Siat8d sialyltransferase 8 (alpha-2, 8-sialyltransferase) 
D
2.08
Dsg2 desmoglein 2 2.07
F11r F11 receptor 2.06
Lrrc33 leucine rich repeat containing 33 2.06
Ian9 Similar to hypothetical protein (LOC243374), 
mRNA
2.06
Slc30a1 solute carrier family 30 (zinc transporter), 
member 1
2.05
Kcnj8 potassium inwardly-rectifying channel, 
subfamily J, member 8
2.05
Cotl1 coactosin-like 1 (Dictyostelium) 2.04
Ptx3 pentaxin related gene 2.04
Ctla2b trophoblast specific protein beta 2.03
Sipa1 signal-induced proliferation associated gene 1 2.03
Rgs5 regulator of G-protein signaling 5 2.03
Itgax integrin alpha X 2.01
Car2 carbonic anhydrase 2 2.01
Serpind1 serine (or cysteine) proteinase inhibitor, clade 
D, member 1
2.01
Cadps2 Ca2+-dependent activator protein for 
secretion 2
2.00
Il1rl2 interleukin 1 receptor-like 2 2.00
Lemd1 LEM domain containing 1 0.06
Gzme granzyme E 0.14
Plekha7 pleckstrin homology domain containing, family 
A member 7
0.14
Chad chondroadherin 0.15
Cd28 CD28 antigen 0.17
Sep-04 septin 4 0.19
Pltp phospholipid transfer protein 0.19
Il15 interleukin 15 0.20
Ttll3 tubulin tyrosine ligase-like family, member 3 0.20
Syt8 synaptotagmin 8 0.20
Gpr91 G protein-coupled receptor 91 0.23
Sep-04 septin 4 0.24
Cd28 CD28 antigen 0.24
Efemp1 epidermal growth factor-containing fibulin-like 
ECM protein 1
0.25
Tnfsf11 tumor necrosis factor (ligand) superfamily, 
member 11
0.27
Tlr1 toll-like receptor 1 0.28
Trim2 tripartite motif protein 2 0.28
Vnn1 vanin 1 0.28
Tnni2 troponin I, skeletal, fast 2 0.29
Enpp6 ectonucleotide pyrophosphatase/
phosphodiesterase 6
0.30
Fxyd2 FXYD domain-containing ion transport 
regulator 2
0.30
Rtn2 reticulon 2 (Z-band associated protein) 0.31
Iqgap2 IQ motif containing GTPase activating protein 2 0.31
Capn6 calpain 6 0.32
Rab27a RAB27A, member RAS oncogene family 0.32
Aicda activation-induced cytidine deaminase 0.33
F5 coagulation factor V 0.33
Hs6st2 heparan sulfate 6-O-sulfotransferase 2 0.33
Cklfsf8 chemokine-like factor super family 8 0.33
Nrk Nik related kinase 0.33
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Gprasp2 G protein-coupled receptor associated sorting 
protein 2
0.33
Car8 carbonic anhydrase 8 0.34
Prom1 prominin 1 0.34
Mgst2 microsomal glutathione S-transferase 2 0.34
Pltp phospholipid transfer protein 0.35
Stc2 stanniocalcin 2 0.35
Lipg lipase, endothelial 0.35
Il17d interleukin 17D 0.36
Serpinb6b serine (or cysteine) proteinase inhibitor, clade 
B, member 6b
0.36
Matn3 matrilin 3 0.37
Slc1a1 solute carrier family 1, member 1 0.37
Art3 ADP-ribosyltransferase 3 0.37
Cp ceruloplasmin 0.37
Abi3bp ABI gene family, member 3 (NESH) binding 
protein
0.37
Matn1 matrilin 1, cartilage matrix protein 1 0.38
A2m alpha-2-macroglobulin 0.38
Usp11 ubiquitin specific protease 11 0.38
Col9a2 procollagen, type IX, alpha 2 0.39
Pik3r1 phosphatidylinositol 3-kinase, regulatory 
subunit, polypeptide 1
0.39
Rlbp1 retinaldehyde binding protein 1 0.39
Rnase4 ribonuclease, RNase A family 4 0.39
Col14a1 procollagen, type XIV, alpha 1 0.40
Slc19a3 solute carrier family 19 (sodium/hydrogen 
exchanger), member 3
0.40
Nfkbiz NFK light polypeptide gene enhancer in B-cells 
inhibitor, zeta
0.40
Slco2b1 solute carrier organic anion transporter family, 
member 2b1
0.41
Fxyd6 FXYD domain-containing ion transport 
regulator 6
0.41
Egr3 early growth response 3 0.41
Usp53 ubiquitin specific peptidase 53 0.41
Serpini1 serine (or cysteine) proteinase inhibitor, clade 
I, member 1
0.41
Pitpnc1 phosphatidylinositol transfer protein, 
cytoplasmic 1
0.42
Anxa8 annexin A8 0.42
Il17b interleukin 17B 0.43
Gpr126 G protein-coupled receptor 126 0.43
Pank1 pantothenate kinase 1 0.43
Dock9 dedicator of cytokinesis 9 0.43
Sfmbt2 Scm-like with four mbt domains 2 0.43
Enpp2 ectonucleotide pyrophosphatase/
phosphodiesterase 2
0.44
Kctd4 potassium channel tetramerisation domain 
containing 4
0.44
Cobll1 Cobl-like 1 0.44
Scrg1 scrapie responsive gene 1 0.45
Matn3 matrilin 3 0.45
Zfpm2 zinc finger protein, multitype 2 0.45
Lims2 LIM and senescent cell antigen like domains 2 0.45
Gpr64 G protein-coupled receptor 64 0.45
Ptprz1 protein tyrosine phosphatase, receptor type Z, 
polypeptide 1
0.46
Hhip Hedgehog-interacting protein 0.46
Eps8 epidermal growth factor receptor pathway 
substrate 8
0.46
Heph hephaestin 0.47
Sesn1 sestrin 1 0.47
Ctf1 cardiotrophin 1 0.47
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Zfp612 zinc finger protein 612 0.48
Wdr40b WD repeat domain 40B 0.48
Dkk1 dickkopf homolog 1 (Xenopus laevis) 0.48
Ogt O-linked N-acetylglucosamine (GlcNAc) 
transferase
0.48
Ddc dopa decarboxylase 0.48
Adam17 a disintegrin and metallopeptidase domain 17 0.48
Rdhe2 short chain dehydrogenase reductase 9 0.48
Vav3 vav 3 oncogene 0.48
Tmem56 transmembrane protein 56 0.48
Aldh1a3 aldehyde dehydrogenase family 1, subfamily A3 0.48
Zfp521 ecotropic viral integration site 3 0.48
Fbxo25 F-box only protein 25 0.49
Kitl kit ligand 0.49
Plagl1 pleiomorphic adenoma gene-like 1 0.49
Hectd2 HECT domain containing 2 0.49
Bmper BMP-binding endothelial regulator 0.49
Gprasp1 G protein-coupled receptor associated sorting 
protein 1
0.50
Gdf10 growth differentiation factor 10 0.50
Sox5 SRY-box containing gene 5 0.50
Table 3: Genes showing 2-fold or greater changes in hypertrophic zone (Continued)
data show that expression of RANKL, a potent activator of
osteoclastic bone resorption, in the hypertrophic zone is
down-regulated by CNP. RANKL is expressed in hyper-
trophic cartilage [35-37], where it likely stimulates the
removal of hypertrophic cartilage by osteoclasts and facil-
itates vascular invasion and ossification. Repression of
RANKL expression by CNP could thus delay these remod-
eling events. Experiments are under way in our laboratory
to examine whether osteoclast activity is indeed reduced
in CNP-treated organ cultures.
We and others have shown important roles of p38 in
hypertrophic chondrocyte differentiation in vitro and in
vivo [3,27,38-41]. Thus, it is not surprising that p38 inhi-
bition reverses CNP effects on longitudinal growth and
the expansion of the hypertrophic zone. Moreover, our
data show that p38 activity is required for the repression
of mineralization by CNP. These data are in agreement
with a recent study showing delayed primary and second-
ary ossification in transgenic mice overexpressing an acti-
vated form of MKK6, an upstream activator of p38, in
cartilage [27]. It should be noted, however, that other phe-
notypes of these mice (such as reduced proliferation and
delayed hypertrophy) are not recapitulated in our studies,
potentially due to altered patterns and/or levels of p38
activation in the two studies (e.g. transgenic expression of
activated MKK6 under the collagen II promoter versus
activation of p38 through the endogenous NPR2/cGMP
signaling cascade) or because CNP acts through addi-
tional pathways besides p38. Independent of these com-
plications, our studies provide strong evidence for a novel
function of p38 signaling in maintaining hypertrophic
cartilage and delaying the replacement of cartilage by
bone.
However, our data also show that p38 signaling is not
required for all effects of CNP on hypertrophic cartilage.
While p38 inhibition results in lower basal levels of Cox2
mRNA in chondrocytes, in agreement with observations
by other studies [42-44], CNP still causes a strong increase
in Cox2 expression in the presence of SB202190. Simi-
larly, Npr3 induction by CNP is independent of p38 activ-
ity. Therefore, it appears likely that p38 signaling is
required to achieve and/or maintain the expanded hyper-
trophic zone in CNP-treated bones, but not for induction
of some target genes. Studies to identify additional signal-
ing pathways connecting CNP to Cox2 gene expression
are underway in our laboratory.
Our studies also demonstrate antagonistic roles of p38
and another MAP kinase pathway, the MEK1/2-ERK1/2
pathway. Inhibition of MEK1/2 activity results in
enhanced growth of endochondral bones, with no addi-
tive or synergistic effect with CNP. While our studies were
in progress, other groups showed that the MEK1/2-ERK1/
2 indeed reduces endochondral bone growth in vivo [26]
and that CNP inhibits ERK1/2 activity [21], in agreement
with our studies. Additional studies confirmed the close
and reciprocal interactions between CNP-cGMP and FGF-
MEK1/2-ERK signaling [22,23]. For example, CNP was
shown to repress FGF-induced growth arrest and extracel-
lular matrix degradation by counteracting MEK1/2 activa-
tion, while FGFs 2 and 18 suppress CNP-stimulated cGMP
production [22,23]. However, none of these studies eval-
uated a potential role of p38 signaling in this context.
Since p38 has also been implicated in FGF signal trans-
duction in chondrocytes [45,46], it will be interesting to
investigate whether this MAP kinase is involved in the
antagonistic effects of CNP and FGF in endochondralBMC Developmental Biology 2007, 7:18 http://www.biomedcentral.com/1471-213X/7/18
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Expression patterns from microarray analyses demonstrate up-regulation of cGMP-dependent kinase genes in the hypertrophic  zone Figure 7
Expression patterns from microarray analyses demonstrate up-regulation of cGMP-dependent kinase genes in 
the hypertrophic zone. Microarray analyses of the principal players in the CNP pathway in micro-dissected tibiae cultured 
with and without CNP (1 μM) are shown (A). Prkg1 and Prgk2, encoding cGMP-dependent kinases I and II, were strongly up-
regulated in the hypertrophic zone, irrespectively of exogenous CNP. In addition, CNP strongly stimulated expression of Npr3, 
the natriuretic peptide clearance receptor, in the hypertrophic zone. Real-time analysis confirmed induction of Npr3 by CNP, 
which primarily occurs through a p38-independent manner. Data represent means ± SD of three independent trials (p < 0.05).
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Detailed analyses of microarray data identify CNP-regulated pathways Figure 8
Detailed analyses of microarray data identify CNP-regulated pathways. Microarray data sets from hypertrophic 
areas of micro-dissected tibiae cultured with and without CNP (1 μM) were analyzed using KEGG annotations (A). Genes up- 
and down-regulated by CNP contributed approximately proportionally to many pathways. However, up-regulated genes dom-
inated the cell adhesion molecules, TGFbeta and calcium signaling and tight junction categories (among others). Fold change of 
selected genes in the BMP/GDF, Wnt and hedgehog pathways in response to CNP is shown (as ratio of CNP to control; B). A 
list of transcription factor genes regulated by CNP is also shown.
A
B
02468 1 0 1 2 1 4
Cell adhesion molecules (CAMs)
Cytokine-cytokine receptor interaction
Focal adhesion
Calcium signaling pathway
Regulation of actin cytoskeleton
TGF-beta signaling pathway
Wnt signaling pathway
Hematopoietic cell lineage
MAPK signaling pathway
Tight junction
Neuroactive ligand-receptor interaction
T cell receptor signaling pathway
Axon guidance
Pentose and glucuronate interconversions
ECM-receptor interaction
Jak-STAT signaling pathway
Pantothenate and CoA biosynthesis
Nicotinate and nicotinamide metabolism
K
E
G
G
 
P
a
t
h
w
a
y
s
Number of Genes
Up-regulated
Down-regulated
Gene Gene Name Fold Change
Hedgehog
Hhip hedgehog-interacting protein 0.46
Wnt 
Dkk1 Dickkopf homolog 1 (Wnt antagonist) 0.48
Srfp2 secreted frizzled-related sequence protein 2 2.39
TGFβ/BMP
Bmper BMP-binding endothelial regulator 0.49
Gdf10 Growth differentiation factor 10 0.5
Inhba Inhibin beta-A 2.28
Inhbb Inhibin beta-B 3.12
Gdf5 Growth differentiation factor 5 4.93
Grem1 cysteine knot superfamily 1, BMP antagonist 1 6.45
Transcription Factors
Egr3 early growth response 3 0.41
Zfpm2 zinc finger protein, multitype 2 (FOG2) 0.45
Sox5 SRY-box containing gene 5 0.5
Six1 sine oculis-related homeobox 1 homolog  2.15
3110018A08Rik Eb3, early B-cell factor 3 2.16
Zfp42 zinc finger protein 42 2.23
Sox18 SRY-box containing gene 18 2.36
Nr2f1 nuclear receptor subfamily 2, group F, member 1 2.55
Runx1 runt related transcription factor 1 2.56
Sox17 SRY-box containing gene 17 3.11BMC Developmental Biology 2007, 7:18 http://www.biomedcentral.com/1471-213X/7/18
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bone growth. However, both CNP and FGFs activate p38
in chondrocytes, but they have opposing effects on the
growth of endochondral bones. The role of p38 in FGF
effects on chondrocytes has, to our knowledge, only been
studied in cell culture, not in a three-dimensional model
that allows direct assessment of bone growth. Based on
our data, we don't expect that p38 activation contributes
to the growth-repressing activities of FGF, but this predic-
tion needs to be experimentally verified. Nevertheless, the
fact that both FGFs and CNP activate p38 despite their
opposing effects on bone growth makes it unlikely that
p38 contributes to crosstalk between the two signaling
systems, in contrast to ERK1/2.
Similarly, it will be important to examine whether regula-
tion of the different MAP kinases by CNP occurs through
independent, parallel pathways, or whether they regulate
each other. In addition, the pathways connecting CNP to
the MAP kinase modules have not been completely
resolved. For example, while it has been shown that
repression of ERK activity by CNP occurs at the level of the
upstream kinase Raf1 and requires cGMP-dependent
kinase activity [22], the exact molecular mechanism
involved has not been described.
This is, to our knowledge, one of the first studies to use
micro-dissection of mammalian endochondral bones for
genome-wide expression analyses by microarrays. We
chose to perform these studies after 6 days of CNP stimu-
lation, as opposed to a short term treatment. While this
approach does not allow us to distinguish direct and indi-
rect target genes of CNP, it mimics the in vivo situation
where cells are exposed to auto-/paracrine CNP signaling
for extended periods. Our study should therefore identify
genes that are regulated by long term exposure to CNP
and are thus likely to be involved in the physiological
activities of CNP in the growing skeleton. Our microarray
data were confirmed by real-time PCR analyses for
selected genes; these data and our earlier studies
[28,47,48] strongly suggest that the vast majority of the
expression profiles detected by our microarrays corre-
spond to the authentic gene expression patterns. Analyses
of array data as well as confirmatory real-time PCRs (e.g.
for type X collagen) also demonstrated that our micro-dis-
section protocol results in efficient separation of different
zones of the cartilage and can be used for identification of
novel hypertrophy-specific genes. Moreover, these data
clearly show that the hypertrophic zone of the growth
plate is by far the most responsive to CNP. This respon-
siveness does not correlate to altered levels of mRNAs for
CNP itself, its signaling receptor, or the decoy receptor in
control conditions. Instead, our data suggest that the
expression of cGMP-dependent kinases I and II (cGKI, II)
is much higher in this zone than in the other ones, provid-
ing further evidence for a crucial role of these enzymes in
CNP signal transduction. Interestingly, the expression of
these two genes, as well as the Nppc and Npr2 genes, in the
hypertrophic zone is not altered in response to CNP. In
contrast, Npr3 expression is strongly induced by CNP in
the hypertrophic zone. While this induction was not iden-
tified as significant in the microarray analyses, subsequent
real-time PCR confirmed the existence of this previously
unknown feedback loop that likely limits CNP effects in
growing cartilage.
Our expression data suggest that both cGKI and II are
involved in mediating CNP effects on cartilage develop-
ment. Studies with genetically altered mice and naturally
occuring rat mutants demonstrate that cGKII is the domi-
nating protein in chondrocytes [19,49]; however, the car-
tilage phenotypes of cGKII- and CNP-deficient mice are
not identical, suggesting the possibility of an additional
role of cGKI in CNP signaling. Double knockout mice for
both cGKI and II will be required to resolve this issue.
Thus, our data in conjunction with published studies sup-
port a model where basal CNP signaling promotes prolif-
eration and extracellular matrix synthesis in growth plate
chondrocytes. Once cells start to differentiate, they
increase their expression of cGMP-dependent kinases and
their responsiveness to CNP. This results in an extension
of hypertrophic chondrocyte life and a delay in osteoclast
and potentially vascular invasion, thus promoting maxi-
mal growth of hypertrophic chondrocytes and endochon-
dral bone growth. At the same time, high levels of CNP
signaling induce expression of Npr3 that ultimately limits
CNP effects, allowing for expression of RANKL and for
remodeling of the metaphysis. Experiments are under way
to examine whether this model accurately describes cellu-
lar mechanisms of CNP signaling in endochondral ossifi-
cation and to identify the molecular mechanisms
involved.
Detailed analyses of our microarray data provided novel
insights into biological processes regulated by CNP. CNP
treatment induced the expression of several genes for cell-
cell interactions in the hypertrophic area (as well as the
resting/proliferating zone), while at the same time
repressing genes for ECM proteins. Another process regu-
lated by CNP is signaling by TGFβ family members. Most
interestingly, CNP induces expression of Gdf5 and Grem1,
both of which have been implicated in skeletal develop-
ment. Loss-of-function mutations of Gdf5 have been iden-
tified as cause of reduced skeletal growth in human
chondrodysplasias and brachypodism mice [50]. Interest-
ingly, GDF5 has been shown to stimulate cell adhesion in
chondrocytes [51], in agreement with our data showing
increased expression of both Gdf5 and cell adhesion mol-
ecules in response to CNP. Therefore, GDF5 is an excellent
candidate for mediating the anabolic effects of CNP. InBMC Developmental Biology 2007, 7:18 http://www.biomedcentral.com/1471-213X/7/18
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contrast, Grem1 encodes a BMP antagonist that is required
for limb development and controls chondrogenesis [52-
56]. Moreover, Grem1 expression is induced by BMP/GDF
signaling [57-59], suggesting that its stimulation could be
secondary to increased expression of Gdf5 and/or related
factors (e.g. Inhbb and Inhba) in response to CNP.
In summary, our results identify several novel compo-
nents and characteristics of CNP signaling during endo-
chondral bone growth. Collectively, these studies lead to
the novel concept that CNP acts, at least in part, by delay-
ing the terminal steps of endochondral ossification, i.e.
the replacement of hypertrophic cartilage by bone. Fur-
ther tests of this model in vivo and elucidation of the
mechanisms involved will not only result in improved
understanding of endochondral bone development, but
will also be crucial for the development of potential ther-
apeutic applications.
Methods
Materials
Timed-pregnant CD1 mice were purchased from Charles
River Canada. CNP, 8-(4-cpt) cGMP, and pharmacologi-
cal inhibitors were obtained from Sigma and Calbiochem.
Cell culture reagents were from Invitrogen and general
chemicals from VWR. All real-time PCR probes and rea-
gents were purchased from Applied Biosystems. The phos-
pho-MKK3/6 (Cat. number 9231) and phospho-p38
(9216) antibodies were from Cell Signaling Technologies,
and the β-actin antibody was from Sigma.
Organ Culture
Tibiae were isolated from embryonic day 15.5 (E15.5)
embryos from CD1 timed-pregnant mice (Charles River
Canada) using the Stemi DV4 Stereomicroscope (Zeiss).
Dissection day was considered to be day 0 and tibiae were
allowed to recover from dissection overnight in serum-
free α-MEM media containing 0.2% Bovine Serum Albu-
min (BSA), 0.5 mM L-glutamine, 40 units penicillin/mL
and 40 μg streptomycin/mL as described [60]. The follow-
ing morning, bones in 24-well Falcon plates were meas-
ured using an eyepiece in the Stemi DV4
Stereomicroscope and treated with CNP (0.01 to 1 μM) or
BSA/HCl (1 mM) vehicle, and DMSO or U0126,
PD98059, PD169316, SB202190 or SB202474 (10 μM
each). Media was changed every 48 hrs beginning on day
1, and bones measured on days 1, 3, 6, and 8. Results are
expressed as change in length relative to day 1. Experi-
ments were repeated at least three times, with 4–6 bones
per treatment for each trial.
For weight determination and Alizarin Red/Alcian Blue
staining, 6 bones per treatment were weighed at day 6 of
culture and then placed in 4% Paraformaldehyde (PFA) in
DEPC-treated PBS for overnight fixation. Subsequently,
tibiae were placed in staining solution for 45–60 minutes
(0.05% Alizarin Red, 0.015% Alcian Blue, 5% acetic acid
in 70% ethanol). Images of stained bones were taken
using a Nikon SMZ1500 dissecting microscope with Pho-
tometric CoolSNAP colour digital camera (Nikon Can-
ada) and PTI Image Master 5 program. Stained areas in
images were measured using Openlab 4.0.4 software pro-
gram.
For experiments requiring perichondrium removal, tibiae
were isolated from embryonic 15.5 day embryos under
three different modes: very loose dissection ensuring that
perichondrium was intact, very careful dissection in which
perichondrium was removed mechanically, and treatment
of tibiae with dispase (3 mg/mL in PBS) for 3–5 minutes
with concurrent mechanical removal of perichondrium
[61,62]. Media was changed every two days beginning on
day 1 and bone lengths measured on days 1 and 6, with
change in length expressed relative to day 1.
Histology and Immunohistochemistry
After experiment completion, tibiae were rinsed with PBS
and fixed in 4% PFA overnight. Bones were then stained
with mercurochrome for visualization, placed in 10% for-
malin solution, and sent for embedding and sectioning in
the Pathology lab at University of Western Ontario Hospi-
tal or the Molecular Pathology Core Facility at the Robarts
Research Institute (London, Ontario, Canada). Following
sectioning, bones were stained with hematoxylin and
eosin using standard protocols. For immunohistochemis-
try, sections were incubated with primary anti-phospho-
p38 antibody (1:50 dilution) over night at 4°C. Bound
antibody was visualized using the UltraVision LPValue
detection system (Lab Vision) with AEC chromogen sub-
strate (Lab Vision).
RNA isolation from organ cultures and microarray 
analyses
For experiments requiring RNA isolation from organ cul-
tures, E15.5 tibiae were harvested and treated as described
above with or without CNP and SB202190. On day 6 of
treatment, tibiae were separated under a dissecting micro-
scope into the resting/proliferative, hypertrophic, and
mineralized areas. Same areas from approximately 24
bones were pooled per trial, in each of three independent
trials. RNA was isolated following the RNeasy ® Lipid Tis-
sue Extraction protocol from Qiagen (Mississauga) and
RNA integrity verified using the Agilent 2100 Bioanalyzer.
Microarray analyses from three trials were performed at
the London Regional Genomics Centre (London,
Ontario, Canada) using MOE430 2.0 Affymetrix arrays
consisting of 45,000 probe sets (covering the entire mouse
genome). Results were analyzed using GeneSpring 7.2
software as described [28]. Microarray data were inde-
pendently filtered using GeneSpring Bioscripts quality fil-BMC Developmental Biology 2007, 7:18 http://www.biomedcentral.com/1471-213X/7/18
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ters for noise and one-way ANOVA testing, to eliminate
genes that were not expressed or showed great variability
between replicates. The remaining 5199 probes sets com-
mon to both filtering methods were used for all subse-
quent analyses. Lists of genes undergoing at least two-fold
changes were analyzed using the Babelomics suite [63]
and in particular the KEGG pathways module in the Fatig-
oPlus tool.
Real-Time PCR
Real-Time PCR analysis was performed as described using
Applied Biosystems 7900 HT Real-Time PCR System and
TaqMan® Gene Expression Assays [28,40,64]. All probes
(Npr3,  Col2a1, Col10a1, Ptgs2,  Tnfsf11  and  Gapdh)were
purchased from Applied Biosystems. Gene expression lev-
els were determined using the Standard Curve quantita-
tive method with Gapdh levels as the basis of comparison.
Statistical Analyses
All experiments were performed in at least three inde-
pendent trials. Two-Way ANOVA (parametric) test with
Bonferroni post-test were performed using the Graph Pad/
Prism software. One-way ANOVA with Bonferroni post-
test and paired t-tests were used when appropriate.
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